Rapid Onset of Cutaneous Adverse Drug Reaction to 2HPMZ/2HPM: A Case Report
DOI:
https://doi.org/10.36497/jri.v46i2.1081Keywords:
2HPMZ/2HPM, adverse effect, cutaneous adverse drug reaction, tuberculosisAbstract
Background: The World Health Organization (WHO) has endorsed the 4-month tuberculosis (TB) regimen, 2HPMZ/2HPM (Isoniazid, Rifapentine, Moxifloxacin, Pyrazinamide), as a non-inferior alternative to the standard six-month course, representing a major advancement in global TB control. While large clinical trials established its general safety, real-world data and management of its cutaneous adverse drug reactions (CADRs) remain limited.
Case: A case of a 19-year-old male initiated on the 2HPMZ/2HPM regimen for pulmonary TB. Within 30 minutes of treatment initiation, the patient developed a maculopapular erythematous rash on both arms and legs. Given the mild degree, the treatment was continued, along with administration of Cetirizine and Prednisone, for 7 days.
Discussion: This case demonstrates safe continuation of treatment following the emergence of mild CADR. CADR can manifest as early as 30 minutes following ingestion, as exhibited in this case. Showing the importance of close initial observation for the 2HPMZ/2HPM regimen. 7-days of antihistamine and corticosteroid administration also appeared to be sufficient when done promptly.
Conclusion: This case demonstrates the safety and feasibility of maintaining the full 2HPMZ/2HPM regimen despite mild cutaneous manifestations, thus avoiding treatment interruption, the need for complex re-challenge protocols, and potential treatment failure.
Downloads
References
1. Rossato Silva D, Carvalho de Queiroz Mello F, Battista Migliori G. Shortened tuberculosis treatment regimens: what is new? Jornal Brasileiro de Pneumologia. 2020;46(2):e20200009.
2. Dorman SE, Nahid P, Kurbatova E V., Phillips PPJ, Bryant K, Dooley KE, et al. Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis. New England Journal of Medicine. 2021;384(18):1705–18.
3. Global Programme on Tuberculosis and Lung Health (GTB). WHO consolidated guidelines on tuberculosis: module 4: treatment: drug-susceptible tuberculosis treatment. WHO; 2022.
4. Koycu Buhari G, Oner Erkekol F, Koca Kalkan I, Ates H, Vural Solak GT, Akkale O, et al. Hypersensitivity reactions with first-line antituberculosis drugs and outcomes of rapid desensitizations. World Allergy Organization Journal. 2024;17(1):100862.
5. Louie JK, Agraz-Lara R, Velásquez GE, Phillips A, Szumowski JD. Experience With Four-Month Rifapentine and Moxifloxacin–Based Tuberculosis Treatment in San Francisco. Open Forum Infect Dis. 2024;11(4):ofae178.
6. Wanichwecharungruang N, Puyati W, Sanchat T. New Tuberculosis Treatment, Old Problems: 100% Adverse Reactions in Thai Tuberculosis Patients on the Rifapentine-Moxifloxacin Regimen. Am J Respir Crit Care Med. 2025;211(Supplement_1):A2400.
7. Peter J, Hoenck H, Lehloenya R. Management of patients with tuberculosis medication-induced drug reaction with eosinophilia and systemic symptoms. Curr Opin Allergy Clin Immunol. 2025;25(4):237–44.
8. Gupta G, Das AK, Kirtana J, Baitha U, Sinha S. Drug-Induced Hypersensitivity Reaction and Re-Introduction of Anti-Tubercular Drugs (ATT): A Case Report and Review of Literature. Journal of Drug Delivery and Therapeutics. 2023;13(6):1–5.
9. Del Pozzo‐Magaña BR, Liy‐Wong C. Drugs and the skin: A concise review of cutaneous adverse drug reactions. Br J Clin Pharmacol. 2024;90(8):1838–55.
10. Cooper D, Ansari MT, Aurelius T, Bobbins A, Dhanda S, Gravel CA, et al. A Scoping Review of Case-Level Causality Assessment Tools Developed Between 2008 and 2023; Strengths, Weaknesses and Potential Future Improvements. Drug Saf. 2026.
11. Murali M, Suppes SL, Feldman K, Goldman JL. Utilization of the Naranjo scale to evaluate adverse drug reactions at a free-standing children’s hospital. PLoS One. 2021;16(1):e0245368.
12. Singh KP, Carvalho ACC, Centis R, D´Ambrosio L, Migliori GB, Mpagama SG, et al. Clinical standards for the management of adverse effects during treatment for TB. The International Journal of Tuberculosis and Lung Disease. 2023;27(7):506–19.
13. Division of Cancer Therapy and Diagnosis National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v6.0 (MedDRA 28.0). U.S. Department of Health and Human Services; 2025.
14. Ma’aruf SY, Sharma A, Fox S, Duarte R, Lange C, Tiberi S. Management of adverse events in TB care and active TB drug safety monitoring. Breathe. 2026;22(1):250203.
15. Kementerian Kesehatan RI. Pedoman Nasional Pelayanan Kedokteran Tata Laksana Tuberkulosis. Jakarta: Kementerian Kesehatan RI; 2020.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Pandu Satya Widiarto, Farchan Azzumar, Khansa Putriana, Erlina Burhan
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
- The authors own the copyright of published articles. Nevertheless, Jurnal Respirologi Indonesia has the first-to-publish license for the publication material.
- Jurnal Respirologi Indonesia has the right to archive, change the format and republish published articles by presenting the authors’ names.
- Articles are published electronically for open access and online for educational, research, and archiving purposes. Jurnal Respirologi Indonesia is not responsible for any copyright issues that might emerge from using any article except for the previous three purposes.
